Fig. 4: Clinical outcomes of 10 SZ patients and 12 SZ+ patients at 12 months following gene-targeted management.

The light green bar indicates seizure stopped; the light purple bar indicates seizures continued with a 50% reduction; the light blue bar indicates seizures continued; the dark green and purple bar shows the number deceased and lost to follow-up, respectively.